mometasone-furoate and Skin-Diseases

To compare the efficacy and safety of mometasone furoate cream 0.1% applied daily versus betamethasone valerate cream 0.1% applied twice daily in a variety of dermatoses.. A 4 week study was undertaken of patients with at least moderately severe dermatoses as judged by scoring of a target lesion. Weekly global improvement was assessed, as well as change in target lesion scores. Local side effects were noted including observation of atrophy.. Fifty eight patients in three centres completed the study, 30 in the betamethasone group and 28 in the mometasone. There was no difference in demographic variables or disease severity in each group or any difference between the three investigator gradings of initial severity. There was a rapid onset of improvement in both groups by day seven (scores being reduced by 72% in the betamethasone group and 65% in the mometasone group). By the fourth week visit there was 90% reduction in the betamethasone group score and 93% in the mometasone. There was no significant difference between the groups.. Mometasone furoate cream 0.1% applied daily in dermatoses is as effective as betamethasone valerate 0.1% cream. Both creams had rapid onset of action and had no signs of atrophy. Better patient compliance could be expected with the convenience of mometasone cream being applied daily.

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone Valerate; Female; Glucocorticoids; Humans; Male; Mometasone Furoate; Pregnadienediols; Remission Induction; Safety; Skin Diseases

The safety and efficacy of once daily application of mometasone furoate cream 0.1% was determined by comparison with twice daily applications of betamethasone dipropionate cream 0.05% in a single blind, dual centre, randomized study in patients with a variety of steroid-responsive inflammatory dermatoses, the most common of which was psoriasis. Morning plasma cortisol levels revealed little adrenal suppression in either of the two study groups and there was no significant difference between the two groups. Routine laboratory investigations showed no trends in values outside the normal ranges that were of clinical significance. Less skin atrophy was seen in the group treated with mometasone furoate. In comparison to the betamethasone dipropionate treated group, those treated with mometasone furoate exhibited only slight evidence of skin atrophy, and this was not observed before four to twelve weeks of treatment. Eighteen percent of patients using mometasone reported adverse reactions but all were of limited duration and did not persist despite continued application of the drug. Nine percent of patients using betamethasone dipropionate reported adverse effects. Both drugs were found to be highly effective with no significant difference between the two groups at the termination of the treatment period. Of importance is the fact that whilst mometasone furoate is found to be a highly effective treatment for a variety of steroid-responsive dermatoses, this drug has only a limited potential for production of local and systemic side effects. Thus, a high margin of safety can be expected for patients using this drug.

Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atrophy; Betamethasone; Female; Humans; Hydrocortisone; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Single-Blind Method; Skin Diseases

Topics: Adult; Dermatologic Agents; Female; Gold Sodium Thiosulfate; Humans; Middle Aged; Mometasone Furoate; Patch Tests; Pseudolymphoma; Skin Diseases

Topics: Animals; Anti-Inflammatory Agents; Bites and Stings; Cetirizine; Clothing; Cnidaria; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Larva; Middle Aged; Mometasone Furoate; Oceans and Seas; Seawater; Skin Diseases; Swimming

For centuries, Hirudo medicinalis (medicinal leech) has been used as a remedy to treat many discomforts, such as muscle and joint pain. Nowadays, using leech in reconstructive surgery, microsurgery, wound and flap healing, venous insufficiency, varicosities and many other disorders has increased. In this study, we report a 45 year old female patient with six pruritic papules on her legs since10 months ago that appeared about 4 weeks after one session of leech application. Skin biopsy was performed on one of the papules, and in histopathology, superficial ulceration with a dense superficial and deep inflammatory infiltrate within the dermis composed of lymphocytes and eosinophils detected that considering history of leech application at this site, these constellation of data was compatible with the diagnosis of cutaneous lymphoid hyperplasia induced by leeches and the patient was cured by a topical steroid and cryotherapy.

Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Female; Hirudo medicinalis; Humans; Leeching; Middle Aged; Mometasone Furoate; Pseudolymphoma; Skin Diseases

A tattoo reaction which appeared solely on the blue pigment of a 6-month old red and blue football club tattoo of an ardent fan was investigated. The patient was otherwise asymptomatic and no other abnormality was detected on full physical examination. Histology revealed a florid sarcoidal granuloma reaction to blue pigment. Preliminary investigations for systemic sarcoidosis did not reveal any abnormality. The tattoo reaction flattened clinically with the institution of a short course of topical mometasone furoate 0.1% ointment and as the subject remained asymptomatic, close surveillance for the development of systemic sarcoidosis is to continue. The possibility of delayed type hypersensitivity is discussed.

Topics: Anti-Allergic Agents; Australia; Coloring Agents; Football; Granuloma; Humans; Hypersensitivity, Delayed; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Sarcoidosis; Skin Diseases; Tattooing

Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Chronic Disease; Humans; Middle Aged; Mometasone Furoate; Pregnadienediols; Skin Diseases; Treatment Outcome

Topics: Anti-Inflammatory Agents; Atrophy; Cortisone; Glucocorticoids; Humans; Methylprednisolone; Mometasone Furoate; Ointments; Pituitary-Adrenal System; Prednisolone; Pregnadienediols; Skin Diseases; Time Factors